Aurobindo Pharma rose 1.56% to Rs 825.95 at 10:04 IST on BSE after consolidated net profit rose 21.4% to Rs 451.76 crore on 14.6% rise in net sales to Rs 3280.11 crore in Q2 September 2015 over Q2 September 2014.
The result was announced after market hours on Friday, 6 November 2015.
Meanwhile, the BSE Sensex was down 369.55 points, or 1.41%, to 25,895.69.
On BSE, so far 54,000 shares were traded in the counter, compared with an average volume of 1.76 lakh shares in the past one quarter.
The stock hit a high of Rs 830.20 and a low of Rs 790 so far during the day. The stock hit a record high of Rs 860.80 on 29 October 2015. The stock hit a 52-week low of Rs 490.50 on 26 February 2015.
The stock had outperformed the market over the past one month till 6 November 2015, rising 7.57% compared with 2.48% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 3.24% as against Sensex's 7.18% decline.
The large-cap company has an equity capital of Rs 58.40 crore. Face value per share is Re 1.
The board of Aurobindo Pharma approved raising funds through issue of equity/global depository receipts (GDRs)/American depositary receipt (ADR)/foreign currency convertible bonds (FCCBs) or any other equity related instruments upto an amount of $600 million or rupee equivalent thereof subject to approval of the shareholders of the company and other necessary approvals. The board has also decided to seek approval of the shareholders through postal ballot for the above purpose. The announcement was made after market hours on Friday, 6 November 2015.
Aurobindo Pharma, headquartered at Hyderabad, manufactures generic pharmaceuticals and active pharmaceutical ingredients (APIs).
Powered by Capital Market - Live News
